NEW YORK – Valo Therapeutics said Tuesday that it has exclusively licensed a microfluidic tumor antigen identification technology, PeptiCHIP, from the University of Helsinki.
Full intellectual property rights will transfer to Valo once the technology has been validated and other milestones have been achieved. The Helsinki-based company will use PeptiCHIP to quickly and cost-effectively identify tumor antigens within cancer immunotherapy development programs and identify personalized approaches.
Valo hopes to eventually commercialize the PeptiCHIP technology and generate revenues from it. The technology also stands to work well with its in-house immunotherapy development tools.
"Precisely knowing the antigen profile of a tumor is crucial in developing new and effective immunotherapies in the treatment of cancer and particularly so when developing a personalized approach," Valo CEO Paul Higham said in a statement. "PeptiCHIP enables us to identify these antigens faster than existing technologies, and, in combination with our lead delivery platform, PeptiCRAd, we see significant potential for the development of personalized cancer immunotherapies across a wide range of cancers."
Valo's peptide-coated conditionally replicating adenovirus, or PeptiCRAd, platform uses immunogenic viruses as carriers of tumor-specific peptides to engage the immune system against cancer cells through three mechanisms: an oncolytic adenovirus, general tumor-specific peptides, and tumor-specific peptides tailored to the patient.
In July 2021, Valo submitted a clinical trial application to the German Regulatory Agency for a Phase I trial of PeptiCRAd-1 (VALO-D102) in combination with Merck's Keytruda (pembrolizumab) in 15 patients with melanoma, triple-negative breast cancer, and non-small cell lung cancer. At the time, the company said it planned to begin dosing patients in the fourth quarter of 2021.